2012 Current Cancer Dedicated to bringing the latest news and information on cancer diagnosis, treatment and prevention.

Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) (“Oncolytics”) announced that an abstract covering preclinical research with reovirus (REOLYSIN®) is available on the European CanCer Organisation (ECCO) website at www.ecco-org.eu. The research is scheduled to be presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16th – 19th 2010.

The abstract, entitled “REOLYSIN® induces endoplasmic reticular stress in multiple myeloma and enhances the activity of bortezomib”, authored by Kelly et al, indicates that the REOLYSIN and bortezomib combination significantly reduced tumor burden in both xenograft and syngeneic multiple myeloma mouse models. The authors concluded that REOLYSIN is a promising anticancer agent that displays activity against multiple myeloma alone and in combination with bortezomib and warrants further investigation for the treatment of multiple myeloma and other malignancies.

“Our preclinical research is increasingly looking at expanding the range of drug combinations and potentially treatable indications that REOLYSIN may be suited for,” said Dr. Matt Coffey, COO of Oncolytics. “With this work we are expanding beyond our research in solid tumours to look at the applicability of our agent in hematopoietic malignancies.”

Source:
Oncolytics Biotech Inc.